Redefining cell line development

Following the launch of Solentim’s new ICON™ instrument and dedicated STUDIUS™ software, the two of which complete the company’s cutting-edge ecosystem, we spoke with Dr Ian Taylor, Chief Business Officer, Solentim, to find out what this means for cell line development and the future of antibody therapeutics.

Read more Redefining cell line development

Solentim to launch the ICON™ in 2021

Solentim is happy to announce that its new Cell Line Development platform, the ICON, will launch early 2021. For over a decade, Solentim has provided leading solutions to create, isolate and characterize the highest value cells, accelerating the development of new biological medicines and therapies around the world, in cell line development, vaccine research, stem …

Read more Solentim to launch the ICON™ in 2021